Comparative Pharmacology
Head-to-head clinical analysis: HEATHER versus IMPLANON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEATHER versus IMPLANON.
HEATHER vs IMPLANON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heather is a combination hormonal contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Drospirenone, a spironolactone analog with anti-mineralocorticoid activity, also inhibits ovulation and may increase cervical mucus viscosity, impeding sperm penetration.
Etonogestrel, a progestin, binds to progesterone and androgen receptors, suppressing gonadotropin release (FSH, LH) and preventing ovulation. It also increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial morphology.
5 mg orally once daily, increased to 10 mg after 2 weeks if tolerated; maximum 20 mg daily.
Insert 1 rod (68 mg etonogestrel) subdermally in the inner upper arm; replacement every 3 years.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours. Clinical context: Requires every-6-hour dosing for steady state; therapeutic drug monitoring recommended in renal impairment.
Terminal elimination half-life is approximately 25-30 hours; significant interindividual variability
Renal excretion of unchanged drug (60%) and hepatic metabolism with biliary/fecal elimination (40%).
Metabolites primarily excreted in urine (approximately 50%) and feces (30-35%)
Category C
Category C
Contraceptive
Contraceptive